Peanut Allergy Therapeutics Pipeline Witnessing Significant Growth due to Rise in the Number of Patents Approvals: P&S Market Research

NEW YORK, March 22, 2018 -- According to a new research report titled “Peanut Allergy Therapeutics Pipeline Analysis 2018” published by P&S Market Research, Peanut allergy therapeutics currently exhibits a proliferating pipeline with 19 drug candidates.

Request for Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/peanut-allergy-therapeutics-pipeline-analysis/report-sample

Peanut allergy is one of the most common type of allergies caused by a legume, known as peanut. Peanut is an annual herbaceous plant that belongs to the family of legumes. Other examples of legumes that can cause the disease include lentils, peas, and soybeans. Peanut allergy can be unpredictable and life-threatening and can bring the body into shock (anaphylaxis). The study analyzed that peanut allergy therapeutics pipeline comprises approximately 19 drug candidates in different stages of development.

According to the research findings, a majority of the drug candidates for the treatment of peanut allergy are being developed to be administered by the oral route which is convenient to take, and has been considered as non-invasive, and is often a safer route that requires no special training to be given to the patients.

Browse Full Report with detailed TOC on “Peanut Allergy Therapeutics Pipeline” at: https://www.psmarketresearch.com/market-analysis/peanut-allergy-therapeutics-pipeline-analysis

It has been observed that most of the companies are developing drug candidates by using advanced technologies and the drug candidates have showed positive efficacy in the clinical as well as Pre-Clinical stage of development. For instance, BioLingus Inc. is utilizing its technology, BioLingus technology, which is a micro-encapsulation process, that delivers macro molecules such as peptides and proteins and is particularly effective for sublingual immunotherapy. With this technology, it has been observed in the Pre-Clinical models that sublingual IL-2 is found efficacious in 500th times lower amount than the investigational sublingual IL-2 therapy for the treatment of peanut allergy.

Some of the key players involved in the development of peanut allergy therapeutics include Aimmune Therapeutics Inc., DBV Technologies S.A., and AnaptysBio Inc.

More Reports Published by P&S Market Research

OX-40 Receptor Agonist Therapeutics Pipeline - https://www.psmarketresearch.com/market-analysis/ox40-receptor-agonist-therapeutics-pipeline

Proteasome Inhibitors Therapeutics Pipeline - https://www.psmarketresearch.com/market-analysis/proteasome-inhibitors-therapeutics

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: [email protected]

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook